Positions

Selected Publications

Academic Article

Year Title Altmetric
2022 Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.  Journal for ImmunoTherapy of Cancer.  10. 2022
2021 Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation.  American Journal of Hematology.  96:E396-E398. 2021
2019 Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications.  Biology of Blood and Marrow Transplantation.  25:233-238. 2019
2018 Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant.  Bone Marrow Transplantation.  53:1345-1348. 2018
2018 Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.  Biology of Blood and Marrow Transplantation.  24:1379-1385. 2018
2017 Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.  Biology of Blood and Marrow Transplantation.  23:269-277. 2017
2017 Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failure.  Bone Marrow Transplantation.  52:157-158. 2017
2016 Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features.  Cancer Causes and Control.  27:81-91. 2016
2015 Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.  Leukemia and Lymphoma.  56:1626-1635. 2015
2015 Telomere length in hematopoietic stem cell transplantation for severe aplastic anemia is it ready for "prime time"?.  JAMA: Journal of the American Medical Association.  313:571-572. 2015

Chapter

Year Title Altmetric
2019 Sources of cells for hematopoietic cell transplantation.  73-84. 2019

Principal Investigator On

Investigator On

  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML  awarded by National Marrow Donor Program
  • Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease  awarded by Emory University
  • IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib  awarded by VANDERBILT UNIVERSITY
  • International Myeloma Foundation Study of the Outcomes of Myeloma Patients with t(11;14) Translocation  awarded by International Myeloma Foundation
  • Molecular Characterization of Myeloma and Related Asymptomatic Precursor States  awarded by National Cancer Institute/NIH/DHHS
  • Multi-center, Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) Regimen  awarded by University of Michigan
  • Private Grant  awarded by AASTROM BIOSCIENCES, INC.
  • Private Grant  awarded by ASTELLAS PHARMA US, INC.
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by ARRAY BIOPHARMA
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC.
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Janssen
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by MUNDIPHARMA
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS, INC.
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program
  • The Role of Exosome Heparanase and miRNAs as Biomarkers for Myeloma  awarded by National Cancer Institute/NIH/DHHS
  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center

    • Education And Training

  • Atlanta Medical Center, Internship
  • Atlanta Medical Center, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • University of Virginia Hospital, Postdoctoral Fellowship
  • Doctor of Medicine in Internal Medicine Residency Program, Medical College of Georgia 1998

    • Full Name

  • Racquel Innis-Shelton